On Monday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's disease and related disorders. The compound exhibits a binding affinity for copper ions, enabling precise regulation of copper metabolism and interacting with essential ions such as copper, iron, and zinc, the company said.
Recent preclinical studies by Recipharm and Smart Assays reveal Telomir-1's strong copper-binding affinity, enabling precise regulation of copper metabolism and interaction with essential ions.
According to the company, these findings position Telomir-1 as a potential breakthrough therapy for Wilson's disease, a rare disorder caused by ATP7B mutations leading to toxic copper buildup in vital organs.
Offering a safer alternative to current treatments, which have significant side effects and require lifelong adherence, Telomir-1 targets the disease's root cause and may qualify for orphan drug designation.
Telomir is also advancing Telomir-1's therapeutic potential in related areas, including Type 2 diabetes and age-related diseases.
The company is optimizing GMP-grade production for IND-enabling studies scheduled for second quarter of 2025, with an IND submission planned for the fourth quarter and first-in-human clinical trials expected by mid-2026. Efforts also include securing an INAD for pets and exploring Telomir-1's dual applications in human and veterinary medicine.
In line with its ethical practices, Telomir discontinued its osteoarthritis study in dogs after the safety phase due to concerns over inducing the condition. The company is now collaborating with a veterinary institution to design a study using elderly dogs naturally affected by osteoarthritis, advancing its INAD application for pets.
"As we look to 2025, Telomir remains dedicated to its mission," said Erez Aminov, Chairman and CEO. "We are pleased to have secured additional financing at a 20% premium with no warrants, providing the resources needed to continue advancing Telomir-1's development while creating value for our shareholders."
Price Action: TELO shares closed 14.10% higher at $5.18 on Friday.
